25 May 2022 in Science Translational Medicine
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses.
3 July 2023 in Nature Communications
Antibody discovery is bottlenecked by the individual expression and evaluation of antigen-specific hits. Here, we address this bottleneck by developing a workflow combining cell-free DNA template generation, cell-free protein synthesis, and binding measurements of antibody fragments in a process that takes hours rather than weeks. We apply this workflow to evaluate 135 previously published antibodies targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including all 8 antibodies previously granted emergency use authorization for coronavirus disease 2019 (COVID-19), and demonstrate identification of the most potent antibodies. We also evaluate 119 anti-SARS-CoV-2 antibodies from a mouse immunized with the SARS-CoV-2 spike protein and identify neutralizing antibody candidates, including the antibody SC2-3, which binds the SARS-CoV-2 spike protein of all tested variants of concern. We expect that our cell-free workflow will accelerate the discovery and characterization of antibodies for future pandemics and for research, diagnostic, and therapeutic applications more broadly.
21 February 2023 in Nature Communications
Functional design of ribosomes with mutant ribosomal RNA (rRNA) can expand opportunities for understanding molecular translation, building cells from the bottom-up, and engineering ribosomes with altered capabilities. However, such efforts are hampered by cell viability constraints, an enormous combinatorial sequence space, and limitations on large-scale, 3D design of RNA structures and functions. To address these challenges, we develop an integrated community science and experimental screening approach for rational design of ribosomes. This approach couples Eterna, an online video game that crowdsources RNA sequence design to community scientists in the form of puzzles, with in vitro ribosome synthesis, assembly, and translation in multiple design-build-test-learn cycles. We apply our framework to discover mutant rRNA sequences that improve protein synthesis in vitro and cell growth in vivo, relative to wild type ribosomes, under diverse environmental conditions. This work provides insights into rRNA sequence-function relationships and has implications for synthetic biology.
13 January 2011 in Zeitschrift für Gastroenterologie
Es wird vermutet, dass Genistein die hepatischen Lipidwerte durch einen Anstieg von Peroxisome Proliferator Activated Receptor Typ α (PPARα) und/oder duch eine Abnahme von aktiviertem Sterol Regulatory Element Binding Protein type 1c (SREBP1c) verbessert. In einem in-vitro Steatosis-Modell an HuH-7-Zellen und primären humanen Hepatozyten untersuchten wir die Einflüsse Genisteins auf den Lipidmetabolismus sowie die vermutlichen Angriffspunkte und den Einfluss auf die Signaltransduktion. Die Zellen wurden zunächst mit Oleat/Palmitat (2: 1) 0,5mM und anschließend 24h mit bis zu 90µM Genistein behandelt. Außerdem wurde Estradiol, der Estrogenrezeptor-Antagonist ICI182780 oder der MEK1/2-Inhibitor PD98059 verwendet, um mögliche Signalwege aufzuklären. Der Lipidgehalt wurde photometrisch nach Ölrot- und SRB-Färbung ermittelt. Zytosol- und Kernprotein wurde isoliert und SREBP1c und PPARα mittels Western Blot gemessen. Weiterhin wurde der mRNA-Gehalt von SREBP1c, PPARα, Fatty Acid Synthase (FASN), Carnitine-Palmitoyl-Synthase Typ 1 Leberform (CPT1L) und Long Chain Acyl-CoA-Synthetase (ACSL) mittels qRT-PCR ermittelt. Genistein senkte konzentrationsabhängig den Lipidgehalt beider Zelltypen. Nukleäres PPARα stieg signifikant nach 60 und 90µM Genisteingabe. Auch wurde ein erhöhter mRNA-Gehalt an PPARα, CPT1L und ACSL gemessen. Die induzierte Steatosis führte zu erhöhten SREBP1c- und FASN-Werten, welche Genistein wiederum senkte, obgleich statistisch nicht signifikant. PD98059 beeinflusste SREBP1c nicht, aber senkte PPARα. Weder ICI182780 noch Estradiol änderten den Effekt Genisteins auf PPARα und SREBP1c. Genistein senkte den Lipidgehalt steatotischer primärer humaner Hepatozyten sowie HuH-7-Zellen effektiv. Erhöhte PPARα-, CPT1L- und ACSL-Werte deuten darauf hin, dass Genistein die β-Oxidation durch eine Steigerung an PPARα verstärkt. Weiterhin senkte Genistein SREBP1c und die Fettsäuresynthese. Genistein kann so die Lipidakkumulation von humanen Hepatozyten reduzieren.
13 January 2011 in Zeitschrift für Gastroenterologie
Hepatic steatosis in the context of nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance. In our study we investigated the effects of genistein on insulin-responsive downstream targets in an in-vitro model of hepatic steatosis. Primary human hepatocytes and HuH-7 cells were treated with oleic and palmitic acid (2: 1 ratio, final concentration 0.5 mM) for 24h to induce an intracellular fat overaccumulation. Oilred O and SRB staining evaluated the in-vitro model of hepatic steatosis. Cells were treated with different concentrations of genistein (7.5 up to 90µM) with increased time (1 up to 36h) of incubation. Different experimental settings with insulin, glucose, estradiol, ICI182780, LY294002 and PD98059 were used to demonstrate pathways and to detect possible targets of genistein. Phosphorylation of IRS-2, Akt and ERK1/2 was detected by western blot. The mRNA expression of insulin receptor, GLUT-2, SREBP-1c, ChREBP and FOXO1 was measured by realtime-PCR.Primary human hepatocytes as well as HuH-7 cells treated with free fatty acids revealed a decreased phosphorylation of Akt and increased levels of SREBP-1c as an evidence of impaired insulin signaling. In addition 90µM genistein applied for 24 hours decreased insulin-induced phosphorylation of Akt but increased phosphorylation of ERK1/2. Furthermore, genistein decreased glucose output of hepatocytes via GLUT-2 transporter at high glucose concentration.Genistein impairs hepatic insulin signaling by inhibiting insulin-induced phosphorylation of Akt in a time and dose-dependent manner. Elevated activation of ERK1/2 is a possible mechanism whereby genistein lowers the lipid content in hepatic steatosis. It is likely that genistein modifies the carbohydrate metabolism via decreased gluconeogenesis and increased glucagon storage. Further studies are needed to elucidate the molecular mechanisms whereby genistein affects hepatic insulin resistance.